Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing

AIDS. 2016 May 15;30(8):1313-5. doi: 10.1097/QAD.0000000000001055.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Dose-Response Relationship, Drug
  • Female
  • Fetal Blood / drug effects
  • Guideline Adherence
  • HIV Infections / drug therapy*
  • HIV Integrase Inhibitors / administration & dosage
  • HIV Integrase Inhibitors / pharmacokinetics*
  • Heterocyclic Compounds, 3-Ring / administration & dosage*
  • Heterocyclic Compounds, 3-Ring / pharmacokinetics*
  • Humans
  • Infant, Newborn
  • Maternal-Fetal Exchange / drug effects*
  • Oxazines
  • Piperazines
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*
  • Pregnancy Outcome
  • Prenatal Exposure Delayed Effects
  • Pyridones
  • Young Adult

Substances

  • HIV Integrase Inhibitors
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • dolutegravir